Jazz Pharmaceuticals PLC Company Profile (NASDAQ:JAZZ)

Jazz Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "JAZZ."

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its quarterly earnings results on Tuesday, May, 9th. The company reported $1.41 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.42 by $0.01. The firm had revenue of $376.10 million for the quarter, compared to analyst estimates of $376.58 million. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. The business's revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.26 earnings per share. View Jazz Pharmaceuticals PLC's Earnings History.

Jazz Pharmaceuticals PLC updated its FY17 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of $10.70-11.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.13. The company issued revenue guidance of $1.625-1.700, compared to the consensus revenue estimate of $1.67 billion.

17 brokerages have issued 1-year target prices for Jazz Pharmaceuticals PLC's shares. Their predictions range from $150.00 to $210.00. On average, they expect Jazz Pharmaceuticals PLC's share price to reach $184.94 in the next year. View Analyst Ratings for Jazz Pharmaceuticals PLC.

Here are some recent quotes from research analysts about Jazz Pharmaceuticals PLC stock:

• 1. Cantor Fitzgerald analysts commented, "Meetings highlight view that late-stage assets are underappreciated. We hosted meetings with the CEO in the Midwest last week. Investors he met with expressed interest in Xyrem, of course, but the bulk of the questions centered around the pipeline. A common theme was that JZP-110 may be underestimated by the Street. We also spoke with some investors who seem to be gaining appreciation for the potential of the low-sodium oxybate formulations. Vyxeos approval could be around the corner. The PDUFA date for Vyxeos is September 30, and management commented that Breakthrough-designated drugs have been approved before the statutory date." (6/27/2017)
• 2. According to Zacks Investment Research, "Jazz’s missed estimates for earnings and sales in the first quarter of 2017. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. However, its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year." (5/15/2017)
• 3. Mizuho analysts commented, "We raise our PT to $162 from $152 while reiterating our Buy rating following positive Phase III data in a key pipeline drug (JZP-110) in obstructive sleep apnea. Our PT went up due to increased likelihood of FDA approval." (3/21/2017)
• 4. Cowen and Company analysts commented, "complete re-rating."Cacciatore comments, "We continue to believe Jazz is nearing a very interesting inflection point, as a favorable resolution to the Xyrem litigation is likely, which could extend the franchise to 2024/2025. Combined with JZP-110's potential $750MM+ opportunity to complement growing Defitelio, Erwinaze, and ultimately Vyxeos, we believe a complete re-rating is nearing. We would add here." (3/20/2017)
• 5. BMO Capital Markets analysts commented, "JAZZ delivered on an important milestone with positive Phase 3 data for JZP-110 in two OSA studies that appear to demonstrate a very solid clinical profile for this novel wake-promoting agent. There had been some concerns into these data (first OSA studies for JZP-110), and we think this outcome significantly de-risks the program; Phase 3 data in narcolepsy set for 2Q17 and filing in late 2017. We reiterate our Outperform; JAZZ remains a top pick." (3/20/2017)

Jazz Pharmaceuticals PLC saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 1,835,939 shares, an increase of 64.9% from the May 31st total of 1,113,578 shares. Based on an average trading volume of 500,285 shares, the days-to-cover ratio is presently 3.7 days. Currently, 3.2% of the company's stock are sold short.

Some companies that are related to Jazz Pharmaceuticals PLC include Grifols, S.A. (GRFS), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), VBI Vaccines (VBIV), Anavex Life Sciences Corp. (AVXL), Mirati Therapeutics (MRTX), XOMA Corporation (XOMA), ContraFect Corporation (CFRX), Aevi Genomic Medicine (GNMX), Trillium Therapeutics (TRIL), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), KaloBios Pharmaceuticals (KBIO), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY), Cubist Pharmaceuticals (CBST) and Dendreon (DNDN).

Jazz Pharmaceuticals PLC's stock is owned by a number of of institutional and retail investors. Top institutional investors include APG Asset Management N.V. (0.46%), Strs Ohio (0.39%), Bank of Montreal Can (0.08%), Fairbanks Capital Management Inc. (0.05%), Livforsakringsbolaget Skandia Omsesidigt (0.04%) and Gateway Investment Advisers LLC (0.03%). Company insiders that own Jazz Pharmaceuticals PLC stock include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals PLC.

Jazz Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, APG Asset Management N.V., Fairbanks Capital Management Inc., Sumitomo Mitsui Asset Management Company LTD, Cardan Capital Partners LLC, Independent Portfolio Consultants Inc., Aperio Group LLC and Xact Kapitalforvaltning AB. Company insiders that have sold Jazz Pharmaceuticals PLC stock in the last year include Bruce C Cozadd, Karen J Wilson, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

Jazz Pharmaceuticals PLC's stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Mn Services Vermogensbeheer B.V., Wellington Shields Capital Management LLC, Russell Investments Group Ltd., Eqis Capital Management Inc., US Bancorp DE, Aviance Capital Partners LLC and Somerset Trust Co. Company insiders that have bought Jazz Pharmaceuticals PLC stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

Shares of Jazz Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Jazz Pharmaceuticals PLC stock can currently be purchased for approximately $161.25.